Polysaccharides (e.g., Cellulose, Etc.) Patents (Class 424/488)
-
Patent number: 8932616Abstract: Hydrophobic ?(1?4)glucopyranose polymers with enhanced degradation properties are described. Between the ?(1?4)glucopyranose polymeric portion and the hydrophobic portion exists a linker portion having a silyl ether chemistry that facilitates degradation of the polymer. Biodegradable matrices can be formed from these polymers, and the matrices can be used for the preparation of implantable and injectable medical devices wherein the matrix is capable of degrading in vivo at an increased rate. Matrices including and capable of releasing a bioactive agent in vivo are also described.Type: GrantFiled: September 30, 2010Date of Patent: January 13, 2015Assignee: Surmodics, Inc.Inventor: Aleksey V. Kurdyumov
-
Patent number: 8932633Abstract: A method of preparing polysaccharide glassy microparticles which are less than 10 ?um in diameter and contain structurally delicate agents, such as proteins, peptides, gene materials, vaccines, antibodies, viruses and liposomes using low-temperature aqueous-aqueous emulsification (free of polyelectrolytes) and freezing-induced phase separation. When delicate agents are added to a polysaccharide-PEG two phase system followed by homogenization (or other shear adding process), the agents partition into the polysaccharide dispersed phase preferentially. These processes help to avoid aggregation of proteins caused by interaction with charged polyelectrolytes used for stabilizing the polysaccharide dispersed phase in our previously reported aqueous-aqueous emulsion. When this system is frozen and lyophilized, glassy particles less than 10 ?m in diameter containing delicate agents can be formed.Type: GrantFiled: July 20, 2006Date of Patent: January 13, 2015Assignee: Biopharm Solutions Inc.Inventors: Tuo Jin, Fei Wu, Weien Yuan
-
Patent number: 8927028Abstract: A dosage form exhibiting delayed transit time through the GI tract. The dosage form comprises a plurality of buoyant particles, each comprising an inner drug-containing core, an intermediate layer surrounding said core and a release rate-controlling outer coating.Type: GrantFiled: December 15, 2005Date of Patent: January 6, 2015Assignee: Jagotec AGInventors: Pascal Grenier, Julien Taillemite, Severine Serreau, Alain Nhamias
-
Patent number: 8927018Abstract: The present invention relates to compositions and methods by which surface modification techniques can be used to modify wide range polymeric or metal substrates using metal nanoparticles.Type: GrantFiled: January 15, 2013Date of Patent: January 6, 2015Assignee: University of Virginia Patent FoundationInventors: Cato T. Laurencin, Lakshmi Sreedharan Nair
-
Patent number: 8920842Abstract: The present invention relates a biopolymeric liquid aqueous composition for producing self-gelling systems and gels, which comprises: an acidic water-based medium, 0.1 to 10% by weight of a pH-gelling acid-soluble biopolymer; and 0.1 to 10% by weight of a water-soluble molecule having a basic character and a pKa between 6.0 and 8.4, or a water-soluble residue or sequence of the molecule having a basic character and a pKa between 6.0 and 8.4. The liquid composition has a final pH ranging from 5.8 and 7.4, and forms a stable solid and homogeneous gel within a temperature range from 10 to 70° C. The present invention also relates to a method for preparing the composition and uses thereof.Type: GrantFiled: October 9, 2009Date of Patent: December 30, 2014Assignee: Piramal Healthcare (Canada) Ltd.Inventors: Abdellatif Chenite, Cyril Chaput, Dong Wang, Amine Selmani
-
Publication number: 20140377354Abstract: The subject of the present invention is a flavoured therapeutic composition containing a clay as the active principle, and characterized in that the clay is a dioctahedral smectite and the flavour is encapsulated.Type: ApplicationFiled: February 12, 2014Publication date: December 25, 2014Applicants: FIRMENICH S.A., IPSEN PHARMA S.A.S.Inventors: Jérôme BARRA, Denis LE HAZIF
-
Patent number: 8916182Abstract: A ‘bioactive’ composition that has one or more oligogalacturonans ((1?4)-?-D-galacturonan) or any other oligosaccharides (oligoguluronans) that may present an ‘egg box’ conformation, this conformation being further stabilized by one or more polycationic saccharide(s), preferably either a chitosan oligosaccharide or a chitosan polysaccharide. A method prepares this composition and it is used, in medical, pharmaceutical, agricultural, nutraceutical, food, feed, textile, cosmetic, industrial and/or environmental applications.Type: GrantFiled: November 28, 2007Date of Patent: December 23, 2014Assignee: Universite de NamurInventors: Pierre Van Cutsem, Juan Carlos Cabrera Pino
-
Patent number: 8911816Abstract: The present invention relates to a new coating composition and especially a new coating composition to be used with a specific coating device for providing an even, thin and enclosing coating on tablets, capsules or pills of different sizes and shapes in order to improve the taste and the swallowing characteristics of the tablets, capsules or pills.Type: GrantFiled: January 20, 2010Date of Patent: December 16, 2014Inventors: Johan Claes Wilhelm Axelsson, Fredrik Robin Lechard Lilieblad
-
Patent number: 8906362Abstract: Provided herein are methods of producing a meniscus scaffold to remove material and increase the pore size and porosity therein. In some embodiments, methods include seeding the tissue with allogeneic or autogeneic cells. Bioscaffolds produced by the processes described herein are also provided, as are methods of treating a subject in need of a bioscaffold implant.Type: GrantFiled: March 23, 2010Date of Patent: December 9, 2014Assignee: Wake Forest University Health SciencesInventors: Cristin M. Ferguson, Mark E. Van Dyke
-
Patent number: 8900623Abstract: The present invention is directed to a composition, kit and method for delivering a soft flowable gel to a flock of poultry in barns, but can also be used in hatcheries or free range farms, for treating poultry with a therapeutic agent. The soft flowable gel comprises water, a gelling agent, a therapeutic agent and between about 0.05% and 0.15% xanthan gum.Type: GrantFiled: July 27, 2010Date of Patent: December 2, 2014Assignee: Vetech Laboratories Inc.Inventor: Eng-Hong Lee
-
Patent number: 8900868Abstract: A medium for growing vascular lineage cells is described. The vascular lineage cell growth medium includes an oligosaccharide-based hydrogel and a growth factor that promotes vascularization by vascular lineage cells.Type: GrantFiled: November 10, 2010Date of Patent: December 2, 2014Assignee: The Johns Hopkins UniversityInventors: Donny Hanjaya-Putra, Sharon Gerecht
-
Patent number: 8895065Abstract: There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts thereof from about 10 mg to about 100 mg in extended release and c) entacapone or salts thereof from about 100 mg to about 1000 mg in immediate release form, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.Type: GrantFiled: May 29, 2012Date of Patent: November 25, 2014Assignee: Wockhardt Ltd.Inventors: Yatendra Kumar Gupta, Girish Kumar Jain, Munish Talwar, Manoj Mashalkar
-
Patent number: 8883184Abstract: Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well as additional beneficial additives. Advantageously, the compositions include further components, such as osteoinductive or osteoconductive materials, medicaments, stem or progenitor cells, and three-dimensional structural frameworks. The compositions are useful for regenerating connective tissue, and can be administered to an area having injury to, or a loss of, connective tissue, such as bone, cartilage, tendon, and ligament.Type: GrantFiled: January 20, 2009Date of Patent: November 11, 2014Assignee: Pioneer Surgical Technology, Inc.Inventors: Ronald Stewart Hill, Richard Chris Klann, Francis V. Lamberti
-
Patent number: 8877243Abstract: A process for making cross-linked polysaccharide gels, particularly cross-linked hyaluronic acid gels, under basic conditions. The resulting gels possess improved degradation characteristics, and are useful in a variety of medical and cosmetic applications.Type: GrantFiled: December 26, 2013Date of Patent: November 4, 2014Assignee: Ultraceuticals R&D Pty., Ltd.Inventors: Simone Charlotte Vonwiller, Geoffrey Kenneth Heber
-
Publication number: 20140322327Abstract: A drug delivery system for sustained delivery of bioactive agents, the system includes a matrix including nanofibrillated cellulose derived from plant based material and at least one bioactive agent, and at least one support selected from synthetic polymers, bio compounds and natural polymers. Also, methods for the manufacture of the system and methods of using it.Type: ApplicationFiled: November 15, 2012Publication date: October 30, 2014Applicant: UPM-KYMMENE CORPORATIONInventors: Antti Laukkanen, Ruzica Kolakovic, Leena Peltonen, Timo Laaksonen, Jouni Hirvonen, Heikki Lyytikainen, Harri Jukarainen, Prijo Kortesuo
-
Patent number: 8871263Abstract: The present invention features a process for making a tablet by (i) compacting a powder blend in a die to form a tablet shape, wherein the powder blend contains a pharmaceutically active agent and a meltable binder and (ii) applying radiofrequency energy to the tablet shape for a sufficient period of time to soften or melt the binder within said tablet shape to form the tablet.Type: GrantFiled: September 22, 2010Date of Patent: October 28, 2014Assignee: McNeil-PPC, Inc.Inventors: Frank J. Bunick, Harry S. Sowden, Joseph R. Luber, Leo B. Kriksunov, Christopher E. Szymczak
-
Patent number: 8858997Abstract: The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.Type: GrantFiled: September 11, 2012Date of Patent: October 14, 2014Assignee: Remedy Pharmaceuticals, Inc.Inventor: Sven Jacobson
-
Patent number: 8859716Abstract: A thiol-ene polymeric material is disclosed. The material is produced by the photopolymerization of reactants having thiol and olefin moieties. The material can incorporate encapsulated components, including cells. Additionally, the material can be derivatized by reacting the polymeric material with components such as proteins.Type: GrantFiled: July 25, 2013Date of Patent: October 14, 2014Assignee: The Regents of the University of ColoradoInventors: Christopher Bowman, Kristi Anseth, Bilge Hacioglu, Charlie Nuttelman
-
Patent number: 8859523Abstract: Described herein are crosslinked compounds useful in numerous treatments. Described herein are methods of making crosslinked compounds via (1) the oxidative coupling of two or more thiol compounds or (2) by the reaction between at least one thiol compound with at least one thiol-reactive compound.Type: GrantFiled: September 19, 2008Date of Patent: October 14, 2014Assignee: University of Utah Research FoundationInventors: Glenn D. Prestwich, Xiao Zheng Shu, Yi Luo, Kelly R. Kirker, Yanchun Liu
-
Patent number: 8858999Abstract: In this invention a two steps procedure is described useful to insert functional groups to the hyaluronic acid (HA), through the formation, in organic solvent, of a particular active group on hydroxyl groups of HA and subsequent substitution, on the inserted active group, with a pendant portion containing at least in its terminal portion a nucleophilic functional group, NH2—R. The group inserted by nucleophilic substitution can contain in another its terminal portion a further nucleophilic functional group, in a way to be easily exploitable to further chemical functionalizations, such as an example to obtain the methacrylation of HA functional groups, to obtain photocrosslinkable derivatives. Both direct derivatives of the proposed process and those obtained by the further functionalization can be employed to produce hydrogels.Type: GrantFiled: January 30, 2009Date of Patent: October 14, 2014Assignee: Universita' Degli Studi di PalermoInventors: Gaetano Giammona, Fabio Palumbo, Giovanna Pitarresi
-
Patent number: 8853361Abstract: The invention relates to a sterile preparation which can be implanted on or in organic tissues, comprising: a natural or modified globin material which is insoluble at physiological pH and/or a material obtainable from globin which has been modified to be soluble at physiological pH, the said materials being biocompatible and biodegradable in the organism; an agent selected from natural or synthetic polymeric adhesive agents, polymeric tissue enhancement or filling agents, more particularly an agent based on crosslinked hyaluronic acid or on polylactic acid, and a polymeric wound cicatrization agent, specifically oxidized cellulose; with the provisos that, if the preparation comprises the said material obtainable from globin modified so as to be at least partly soluble, the said polymeric adhesive agent, if present, is not hyaluronic acid or carboxymethylcellulose and the said polymeric enhancement or filling agent, if present, is an agent based on crosslinked hyaluronic acid, and that, if the preparation comType: GrantFiled: January 24, 2007Date of Patent: October 7, 2014Assignee: KhorionyxInventor: Jean-Louis Tayot
-
Publication number: 20140294960Abstract: Implantable modular hydrogels to aid in salivary gland restoration and associated methods are provided. In one embodiment, the present disclosure provides for a hydrogel network comprising: a hyaluronic acid macromer crosslinked with a multiblock copolymer.Type: ApplicationFiled: June 16, 2014Publication date: October 2, 2014Inventors: Robert L. Witt, Xinqiao Jia, Swati Pradham Bhatt, Mary C. Farach-Carson, Daniel A. Harrington
-
Publication number: 20140294953Abstract: The disclosure relates to a sustained-release oral dosage form for once-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydromorphone. The dosage form can have a release profile such that 16 hours following administration, less than about 85 percent of the hydromorphone is released. In addition, the dosage form may have alcohol and/or crush resistance.Type: ApplicationFiled: June 5, 2014Publication date: October 2, 2014Inventors: Ehab Hamed, Manuel A. Vega Zepeda
-
Patent number: 8846094Abstract: Viscous formulations and methods of using such compositions, useful for intramuscular and intra-articular injection are provided to treat peripheral conditions. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. In a most preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 280,000 cps at a shear rate of 0.1/second at 25° C. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.Type: GrantFiled: July 26, 2007Date of Patent: September 30, 2014Assignee: Allergan, Inc.Inventors: Robert T. Lyons, Michael R. Robinson, John T. Trogden, Scott M. Whitcup
-
Patent number: 8846095Abstract: A tissue adhesive formed by reacting an aminodextran containing primary amine groups with an oxidized dextran containing aldehyde groups is described. The dextran-based polymer tissue adhesive is particularly useful in medical applications where low swell and slow degradation are needed, for example sealing the dura, ophthalmic procedures, tissue repair, antiadhesive applications, drug delivery, and as a plug to seal a fistula or the punctum.Type: GrantFiled: November 14, 2008Date of Patent: September 30, 2014Assignee: Actamax Surgical Materials, LLCInventor: Helen S. M. Lu
-
Patent number: 8846103Abstract: The disclosure provides cross-linked materials that include multivalent cross-linking agents that bind an exogenous target molecule; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, wherein the two or more affinity ligands compete with the exogenous target molecule for binding with the cross-linking agents and wherein conjugates are cross-linked within the material as a result of non-covalent interactions between cross-linking agents and affinity ligands on different conjugates. The conjugates also include a drug.Type: GrantFiled: January 27, 2010Date of Patent: September 30, 2014Assignee: SmartCells, Inc.Inventors: Todd C. Zion, Thomas M. Lancaster
-
Publication number: 20140271867Abstract: The present invention includes a pharmaceutical-based film system which includes various small-scale forms of pharmaceutically active agents, including testosterone esters, in a film base. Such forms include nanoparticles, microparticles, and combinations thereof. Methods of producing such film and providing a dosage of the pharmaceutical in a film are also provided.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: MONOSOL RX, LLCInventor: Garry L. Myers
-
Publication number: 20140271868Abstract: The present invention relates to a method for the treatment of skeletal dysplasia by administering to a patient a composition comprising a therapeutically effective amount of at least one C-type natriuretic peptide (CNP).Type: ApplicationFiled: April 17, 2014Publication date: September 18, 2014Applicant: HEPACORE LIMITEDInventors: Myriam Golembo, Avner Yayon
-
Patent number: 8834889Abstract: An antigen presenting composition comprising a plurality of 2-component MHC class I complexes and a carrier is described. A method for activating a group of antigen-specific CD8+ T cells comprising incubation of a group of naïve CD8+ T cells with the antigen presenting composition is also presented. A method for inducing the proliferation of a group of antigen-specific CD8+ T cells comprising incubation of a group of naïve CD8+ T cells with the antigen presenting composition is further described.Type: GrantFiled: August 29, 2011Date of Patent: September 16, 2014Assignee: National Tsing Hua UniversityInventor: Chien-Chung Chang
-
Patent number: 8834937Abstract: A bone filling material comprising sintered titanium dioxide and dextrin and a method for reconstructing bone defects which comprises filling the bone defects in an animal with the bone filling material. The bone filling material of the invention has excellent cell compatibility, biocompatibility and shape-imparting property.Type: GrantFiled: September 10, 2010Date of Patent: September 16, 2014Assignees: Aichi Gakuin, Matsutani Chemical industry Co., Ltd.Inventors: Takafumi Asai, Tatsushi Kawai
-
Patent number: 8833378Abstract: A method for the preparation of a nicotine-cellulose combination, the method comprising simultaneous loading of the nicotine on the cellulose and agglomeration of the particles so as to obtain a suitably loaded combination with a mean particle size that is suitable for use e.g. in snuff compositions packed in pouches of gauze or other materials with opening. The invention further relates to the use of such a nicotine-cellulose combination for the preparation of a snuff composition for achievement of a fast onset of action of nicotine after application of the snuff composition to the oral cavity of a subject, wherein the composition has a high release rate so that when subjected to an in vitro dissolution test about 45% or more of the total content of nicotine is released within 30 minutes. Moreover, the invention relates to an improved snuff composition for application to the oral cavity.Type: GrantFiled: September 17, 2009Date of Patent: September 16, 2014Assignee: Niconovum ABInventors: Anders Axelsson, Arne Kristensen
-
Patent number: 8821936Abstract: This invention provides a solid pharmaceutical formulation having high physical strength and further having excellent drug release properties and digestibility of excipients when administered, which comprises (a) an active medical ingredient and (b) a pre-gelatinized starch in an amount of 10 to 90% by weight, said pre-gelatinized starch being prepared by pre-gelatinizing a cheap and stable usual starch during the procedure for formulation. This invention also provides a method for preparing the solid pharmaceutical formulation.Type: GrantFiled: May 19, 2005Date of Patent: September 2, 2014Assignee: Otsuka Pharmaceutical Co., Ltd.Inventor: Tadashi Mukai
-
Patent number: 8821933Abstract: Methods and compositions related polymers and hydrogels. In some cases to biodegradable hydrogels for use in medical applications are disclosed. The polymers and hydrogels may be produced from cross-linked dextran and poly(epoxides). The poly(epoxides) may be poloxamers.Type: GrantFiled: November 1, 2011Date of Patent: September 2, 2014Assignee: nanoDERM Sciences, Inc.Inventors: Roy R. Yeoman, Adrian S. Fox
-
Patent number: 8822676Abstract: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.Type: GrantFiled: March 13, 2012Date of Patent: September 2, 2014Assignee: Allergan Industrie, SASInventor: Pierre F. Lebreton
-
Patent number: 8821932Abstract: A process for the production of a composition comprising a water-insoluble statin which comprises the steps of: a) providing a mixture comprising: i) a water-insoluble statin ii) a water soluble carrier, iii) a solvent for each of the statin and the carrier, and b) spray-drying the mixture to remove the or each solvent and obtain a substantially solvent-free nano-dispersion of the statin in the carrier.Type: GrantFiled: June 29, 2007Date of Patent: September 2, 2014Inventors: David John Duncalf, Alison Jayne Foster, James Long, Steven Paul Rannard, Dong Wang
-
Patent number: 8820331Abstract: A smoking device includes a recipient or able to receive burning (i.e., burnable) products, preferably tobacco, and a filter element connected to the recipient, wherein the filter includes at least one breakable capsule, the capsule having a initial crush strength from 0.5 to 2.5 kp, and keeping a crush strength from 0.5 to 2.5 kp and a deformation of less than two third of its diameter prior to rupture after having been submitted to a smoking test. The invention is also relating to the capsule suitable for being incorporated in a smoking device, and to the process of manufacture of the capsule.Type: GrantFiled: June 21, 2006Date of Patent: September 2, 2014Assignee: V. Mane FilsInventors: Didier Hartmann, Jean-Michel Hannetel, Nathalie Coursieres, Jean Mane
-
Publication number: 20140242162Abstract: The invention relates to extended release pharmaceutical formulations in form of multiparticulates comprising 40-O-(2-hydroxy)ethyl-rapamycin, to dosage forms which comprise said pharmaceutical formulations, to methods of preparing said pharmaceutical formulations and said dosage forms, to uses of said pharmaceutical formulations and said dosage for the manufacture of a medicament for the treatment or prevention of diseases or conditions responsive to inhibition of mTOR signaling pathway, such as for instance proliferative diseases or immunosuppression.Type: ApplicationFiled: October 3, 2012Publication date: August 28, 2014Inventors: Anke Diederich, Kurt Liechti, Peter Kuehl, Wing Cheung
-
Publication number: 20140234212Abstract: A delivery device for topical and systemic delivery of agents to targeted oral locations, such as mouth cancer cells, has been developed. The formulation includes a mucoadhesive polymeric matrix such as chitosan, which contains one or more therapeutic and/or diagnostic agents, taste masking agents, permeation enhancers, the therapeutic or diagnostic agent to be delivered, and a hydrophilic polymeric coating such as polyethyleneglycol (“PEG”). In the preferred embodiment, the matrix is formulated with one side having the PEG-mucoadhesive polymer exposed for topical placement onto epithelial or cancer cells in the mouth or other mucosal area and the side(s) facing the inside of the oral cavity being covered with a biocompatible, inert membrane that is impermeable to the therapeutic and/or diagnostic agent(s) to be delivered.Type: ApplicationFiled: February 21, 2014Publication date: August 21, 2014Applicant: Massachusetts Institute of TechnologyInventors: Manijeh Nazari Goldberg, Maria Jose Alonso, Kuan-Ju Chen
-
Patent number: 8795715Abstract: The invention relates to novel powderous, water-soluble compositions of fat-soluble substances and aqueous solutions or emulsions thereof, wherein the fat-soluble substance(s) are encapsulated as inner (discontinuous phase) within an outer (continuous) phase of a matrix substance.Type: GrantFiled: June 21, 2010Date of Patent: August 5, 2014Assignee: DSM IP Assets B.V.Inventor: Elger Funda
-
Patent number: 8796341Abstract: A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.Type: GrantFiled: June 11, 2013Date of Patent: August 5, 2014Assignee: Bend Research, Inc.Inventors: William J. Curatolo, Ravi M. Shanker, Walter C. Babcock, Dwayne T. Friesen, James A. S. Nightingale, Douglas A. Lorenz
-
Patent number: 8790631Abstract: The invention relates to a biocompatible polymer having general formula (I) AaXxYy, wherein: A denotes a monomer; X denotes an RCOOR? group; Y denotes an O or N-sulphonate group which is fixed to A and which has either formula —ROS03R? or —RNS03R? in which R denotes an optionally branched and/or unsaturated aliphatic hydrocarbon chain which can contain one or more aromatic rings and R? denotes a hydrogen atom or a cation; a denotes the number of monomers; x denotes the rate of substitution of the A monomers by the X groups; and y denotes the rate of substitution of the A monomers by the Y groups. More specifically, the invention relates to the use of said biocompatible polymers for the preparation of a pharmaceutical, dermatological or cosmetic composition or a medical device, which are intended to prevent, relieve and/or treat discomfort, distress, itches, irritations and/or pain and/or to protect tissues against same.Type: GrantFiled: October 28, 2004Date of Patent: July 29, 2014Assignees: Organes Tissus Regeneration Reparation Replacement—OTR3Inventors: Denis Barritault, Veronique Barbier-Chassefiere
-
Patent number: 8790701Abstract: The present invention provides biocompatible, biodegradable matrices formed from poly-?(1?4)glucopyranose and reactive hydrazide groups. The matrices can be used for various applications in the body, including drug delivery and cell therapy.Type: GrantFiled: April 27, 2009Date of Patent: July 29, 2014Assignee: SurModics, Inc.Inventors: Emily R. Rolfes, Jeff J. Ross, Joseph S. McGonigle, Gary W. Opperman, Pamela J. Reed
-
Patent number: 8790702Abstract: The present application provides compositions comprising hyaluronic acid having low levels of functional group modification, mixtures formed by controlled reaction of such lightly modified hyaluronic acid with suitable difunctional or multi-functional crosslinkers, and hydrogel precursor compositions and the resulting hydrogels. The compositions are lightly cross-linked and possess low pro-inflammatory properties when injected in vivo, and can be used as, for example, medical devices, biomedical adhesives and sealants, and for localized delivery of bioactive agents, among other uses.Type: GrantFiled: July 23, 2010Date of Patent: July 29, 2014Assignee: Carbylan Therapeutics, Inc.Inventors: David M. Gravett, George Y. Daniloff, Pingren He
-
Patent number: 8790695Abstract: A medicinal carrier is provided. The medicinal carrier comprises a first component, which is a biocompatible polymer with an amino group (—NH2); a saccharide; and a second component which is a biocompatible material. The saccharide grafts to the first component via the amino group (—NH2) of the first component, and the first component bonds to the second component via an ionic bond. The medicinal carrier can protect the medicine from gastric acid and swell or decompose to release the medicine under a specific pH condition, thus, showing a good applicability.Type: GrantFiled: November 27, 2012Date of Patent: July 29, 2014Assignee: China Medical UniversityInventor: Yu-Hsin Lin
-
Patent number: 8785418Abstract: Lyophilized cakes of proteasome inhibitors are described, as well as methods for their production and use.Type: GrantFiled: September 29, 2011Date of Patent: July 22, 2014Assignee: Cephalon, Inc.Inventors: Denis Bricout, Helene Cambourieux, Michael L. Cappola, Nicole Frati, Piyush R. Patel
-
Patent number: 8784893Abstract: Disclosed in the present application are compositions comprising a bioresorbable polymer matrix and a bio active agent, wherein the bioactive agent is dispersed within polymer matrix as a solid. Also provided herein are methods for preparing a bioactive agent formulation, wherein the agent is present in a solid form and, wherein the agent is occluded into a polymeric matrix by polymerization of polymer matrix precursors or by self assembly of the polymer.Type: GrantFiled: February 5, 2008Date of Patent: July 22, 2014Assignee: Carbylan Therapeutics, Inc.Inventors: George Daniloff, David Gravett, Robert C. Spiro
-
Publication number: 20140199394Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.Type: ApplicationFiled: March 14, 2014Publication date: July 17, 2014Applicant: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Hua-Pin HUANG, John K. Masselink, Alfred Tonelli
-
Patent number: 8778399Abstract: Tablets and other objects are film coated by including in the tablet a film-forming polymer that is activated upon contact with an activating amount of liquid. The film-forming polymer, e.g., a cellulosic ether, is homogeneously mixed with the other ingredients of the tablet, shaped into any desirable form, loaded into a conventional coating apparatus, and sprayed or foamed with an activating amount of fluid, e.g., water, alcohol, etc., and dried. This coating process eliminates potential problems such as spray nozzle clogging, inappropriate coating fluid viscosity, and the inability to properly atomize the coating fluid. This coating process does not impart any appreciable weight or thickness gain to the tablet.Type: GrantFiled: June 2, 2008Date of Patent: July 15, 2014Assignee: Dow Global Technologies LLCInventors: Paul J. Sheskey, Colin M. Keary
-
Patent number: 8778909Abstract: Methods for applying injectable fillers are provided. In some embodiments, the methods can extend effectiveness of the injectable filler. In some embodiments, the methods can provide for an elevated level of effectiveness of the injectable filler. In some embodiments, the methods can prolong the effectiveness of the injectable filler.Type: GrantFiled: May 31, 2013Date of Patent: July 15, 2014Assignee: Medicis Pharmaceutical CorporationInventors: Mitchell S. Wortzman, Rhoda Narins, Xiaoming Lin
-
Patent number: 8778369Abstract: Long-lasting persistent, uniform, film-forming skin protecting compositions provide long-lasting persistent barrier films when applied to skin. The compositions have particular utility as barrier teat dips for protecting cows against mastitis and as wound care agents. A barrier film-forming agent is selected from pullulan, pullulan derivatives and combinations thereof. The barrier film-forming agent is stably solubilized in a solvent that dries to form the long-lasting, persistent, uniform film over the animal skin. The compositions may contain additives, such as antimicrobial agents that kill microorganisms.Type: GrantFiled: May 22, 2009Date of Patent: July 15, 2014Assignee: DeLaval Holding ABInventors: Fahim U. Ahmed, N. Camelia Traistaru